Navigation Links
EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application
Date:11/30/2009

ROCKLAND, Mass., Nov. 30 /PRNewswire/ -- EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a refuse to file letter from the US Food and Drug Administration (FDA) on the New Drug Application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing forms of multiple sclerosis (MS).

"The company will work closely with the FDA to fully understand FDA's concerns and define a path forward for a successful resubmission of this application at the earliest point in time," said Elmar Schnee, Member of the Executive Board Merck KGaA and Head of Pharmaceuticals. "We remain focused on delivering on our promise to transform the way people living with multiple sclerosis approach their therapy options."

Based on current regulations, once a NDA is submitted to the FDA, the Agency has 60 days to preliminarily review the NDA submission and assess whether the NDA is sufficiently complete to permit a substantive review. If it determines that the NDA is not sufficiently complete, the FDA issues a refuse to file letter to the applicant. EMD Serono plans to request a meeting with the FDA as soon as possible to discuss its comments on the NDA submission and to reach an understanding on what would be required for the Cladribine Tablets NDA to be accepted for review.

About Cladribine Tablets

EMD Serono's oral formulation of cladribine (Cladribine Tablets) is an investigational treatment for patients with relapsing forms of multiple sclerosis (MS). Cladribine is a small molecule that may interfere with the behavior and the proliferation of certain white blood cells, particularly lymphocytes, which are thought to be involved in the pathological process of MS.

The clinical development program for Cladribine Tablets includes:

  • The CLARITY (CLAdRIbine Tablets Treating MS OrallY) study and its extension: a two-year Phase III placebo-controlled trial designed to evaluate the efficacy and safety of Cladribine Tablets as a monotherapy in patients with relapsing-remitting MS and its two-year extension designed to provide data on the long-term safety and efficacy of extended administration of Cladribine Tablets for up to four years.
  • The ORACLE MS (ORAl CLadribine in Early MS) study: a two-year Phase III placebo-controlled trial designed to evaluate the efficacy and safety of Cladribine Tablets as a monotherapy in patients at risk of developing MS (patients who have experienced a first clinical event suggestive of MS). This trial was announced in September 2008.
  • The ONWARD (Oral Cladribine Added ON To Interferon beta-1a in Patients With Active Relapsing Disease) study: a Phase II placebo-controlled trial designed primarily to evaluate the safety and tolerability of adding Cladribine Tablets treatment to patients with relapsing forms of MS, who have experienced breakthrough disease while on established interferon-beta therapy. This trial was announced in January 2007.

About multiple sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that more than two million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

About EMD Serono

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, with Rebif® (interferon beta-1a), as well as in endocrinology, with Saizen® (somatropin (rDNA origin) for injection) and Serostim® (somatropin (rDNA origin) for injection). EMD Serono is a leader in reproductive health, with Gonal-f® (follitropin alfa for injection), Luveris® (lutropin alfa for injection) and Ovidrel® Prefilled Syringe (choriogonadotropin alfa injection). With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono's US footprint continues to grow, with more than 1000 employees around the country and fully integrated commercial, clinical and research operations in the company's home state of Massachusetts.

For more information, please visit www.emdserono.com

About Merck

Merck is a global pharmaceutical and chemical company with total revenues of 7.6 billion euros in 2008, a history that began in 1668, and a future shaped by approximately 33,000 employees in 60 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit www.merckserono.com or www.merck.de

SOURCE EMD Serono, Inc.


'/>"/>
SOURCE EMD Serono, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
2. EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States
3. Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
4. EMD Serono and FAST FORWARD, LLC Announce Collaboration to Accelerate Development of Treatments for Multiple Sclerosis
5. EMD Serono, Inc. Announces Expansion with Research Site in Cambridge, Massachusetts
6. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
7. DaVita Receives Civil Complaint
8. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
9. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
10. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
11. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... , ... January 14, 2017 , ... Wondering where to ... Dinner delivered straight to your door for a romantic, lobster feast in the comfort ... time for Valentine's Day. The dinners will be featured until February 15th, 2017. ...
(Date:1/14/2017)... Minneapolis, MN (PRWEB) , ... January 14, 2017 ... ... to present the distinctions among their expanding line of activated charcoal products. With ... emphasizes the importance of categorizing their products according to how they cater to ...
(Date:1/14/2017)... ... January 14, 2017 , ... "TransFreeze Volume 3 is a self animating masking transition which ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... frame transition from one clip to the next. , To use “Cut-Out First” ...
(Date:1/13/2017)... ... 2017 , ... A January 10 article in the Daily Star ... publication, with an emphasis on some new techniques that the publication says are becoming ... more casually to his patients and colleagues as Dr. J, comments that the best ...
(Date:1/13/2017)... ... ... An inventor from Pahrump, Nev., used an unsavory medical experience to think of a way ... and urine bag for a half year due to lazy bladder," he said. "Keeping these ... a better way to do this." , He then designed and created a prototype of ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... N.J. , Jan. 16, 2017   Linde Gas ... all of the assets and business of The Service Center ... equipment repair services to healthcare providers in the Midwest and ... Broadview, Illinois , The Service Center also ... Greenville, South Carolina . Its primary services ...
(Date:1/16/2017)...  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is pleased to ... CFA to its Board of Directors. He is the ... Management LLC . He is also the Chief Investment ... advisory firm with over $1.5 billion under management. ... security analysis and portfolio management. He began his career ...
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP announces ... purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ... October 31, 2016 (the "Class Period"). Zimmer Biomet ... markets orthopaedic reconstructive products, such as knee and hip reconstructive ... ...
Breaking Medicine Technology: